Cancer Research UK’s spin-out, GammaDelta Therapeutics, has been given approval to trial its unique T-cell therapy in the US.
Scientists are developing a new drug for treating acute myeloid leukaemia (AML), a type of blood cancer that affects around 3,100 people in the UK each year.
New research shows a type of aggressive blood cancer could be made more sensitive to chemotherapy using an antibiotic currently available to treat diarrhoea.
Researchers in Cambridge have pioneered the development of an innovative affinity maturation technique to generate high-affinity antibody against Arginase 2.
The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.
The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland
Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.
Patients living with a specific type of leukaemia will have access to a new immunotherapy treatment on the NHS in England.
Patients with a specific type of leukaemia will not have access to a new treatment after it failed to win provisional recommendation for NHS use in England.
Two cancer immunotherapies have been reviewed for NHS use in Scotland as a treatment for some patients with aggressive blood cancer.